CoQsource® Bio-Enhanced Coenzyme Q10

Product Description
Coenzyme Q10 is found in every cell in your body as it is a critical component to energy production at the cellular level. In fact, due to its universal presence in cells, its chemical name is not surprisingly, “ubiquinone,” which is synonymous with “ubiquitous,” or “ever-present.”

Every cell in the body requires CoQ10 for energy production and antioxidant protection, and to enable all cells, tissues and organs to function normally. It is found in every cell of the body and is important for many organs and functions in the body that require a lot of energy, including the heart, brain and immune system, so it is not surprising that CoQ10 is highly concentrated in major organs - the heart, brain, liver and kidneys.

This is particularly important to overall health and energy levels, as our body’s natural levels of CoQ10 decrease with age. CoQ10 supports our body’s ability to help manage stress, which tend to manifest with increasing frequency as we get older. The need for supplementing with CoQ10 is clear and has never been greater. The importance of improving uptake, absorption, and bioavailability is also quite evident.

The worldwide introduction of CoQsource® - featuring VESIsorb® delivery system – for oral application represents a unique and patented solution to improve the absorption of poorly water soluble bio-actives, especially CoQ10 in either the ubiquinol or ubiquinone form.

Please click here for CoQsource® White Paper.

Market Opportunity
A generally accepted state of “good health” exists when our major tissues and organs optimally produce energy and protect themselves from oxidation. The commonly understood role of CoQ10 in cellular function has helped produce a growing awareness of the value of CoQ10 in health and wellness. The fact that both CoQ10 levels and the body’s ability to manufacture CoQ10 decrease with age, at the same time as we generally need more energy, support for life and protection from stress and a weakened immune system. To make up for this depletion, many people supplement CoQ10, at the same time as the ability of the digestive system to absorb nutrients is also decreasing. As a result, the ability to absorb and utilize CoQ10, becomes and even more critical factor.

Further, the need for supplementing with CoQ10 has never been greater, especially with the dramatic increase in the number of people taking statin drugs. It is well established that statins lower cholesterol by blocking cholesterol synthesis. But statins also block the body’s natural CoQ10 production and deplete CoQ10 stored in the body.

Other factors - aging, illness, disease, degenerative ailments, over-exertion, exposure to chemicals, and lack of a proper diet, to name a few - can also contribute to lower levels of CoQ10. Greater focus is being placed on not only the quality of the CoQ10, but more importantly the amount absorbed into the body. For these reasons, the need for a highly bioavailable CoQ10 has never been greater. Higher absorption translates to greater support of the cardiovascular system; improve function of the mitochondria, reduced production of free radicals, more energy, stamina, and endurance. SourceOne’s CoQsource® is the unique, patented solution to superior CoQ10 absorption.

Please click here for CoQsource® FAQ

Innovation:
The technology was developed by Vesifact and is protected worldwide by multiple U.S. and international granted and pending patents. The patented VESIsorb® delivery system is a naturally self-assembling colloidal delivery system that has been clinically proven to increase absorption of medical, nutraceutical, food, beverage, and cosmetic ingredients. The Vesifact VESIsorb® technology is licensed exclusively to SourceOne.

Solutions:
CoQsource® is available in various potencies from 50mg to 200mg in soft gel capsules. It is also available in a novel, proprietary two-piece liquid-filled hard shell capsule, Caplique™, an exclusive from AquaCap, a member of Atrium Innovations’ family of companies.

Our compelling technologies allow us to use the VESIsorb® delivery system in broader applications including:

two-piece powder-filled hard caps
vegicaps
tablets

These technologies are also suitable for instant powder applications including:

beverage powder sachets
meal replacement shakes
protein shakes, and more.

Moreover, Omega-3 can be formulated into the VESIsorb® delivery system with CoQ10 to offer a unique formula in a patented naturally self-assembling association colloidal delivery system.

All of the various VESIsorb® formulas from CoQsource® to combinations of CoQ10 with Omega-3, palm tocotrienol, and more are available in both oil and powder forms.

Clinical Science:
Depleted CoQ10 has been associated with a range of heart conditions (including arrhythmias, strokes, hypertension, heart attacks, and atherosclerosis), and CoQ10 can help prevent and treat these conditions. It also is associated with helping to prevent oxidation of LDL cholesterol. Because of its central role in cell development, it is an energy and brain booster, and can assist in weight loss due to its ability to help speed up metabolism of fats. It has also been successful in fighting periodontal diseases like gingivitis, and in some studies has demonstrated effectiveness as a supplement in treatment of certain cancers, including breast cancer.

In our study ("Relative bioavailability comparison of different Coenzyme Q10 formulations with novel self-assembling association colloid delivery system"; published in Alternative Therapies in Health & Medicine 15(2) 2009, 42-49) CoQsource® was not compared to crystal CoQ10 powder. Three “bio-enhanced” formulas were selected, an oily suspension and two solubilizates.

Please click here to view the full study

A pharmacokinetic pilot study (single oral dose, crossover) in humans comparing ubiquinol-QH to the same ubiquinol-QH in the VESIsorb® delivery system (CoQsource® QH exclusively from SourceOne) demonstrated an increase of 696% in peak blood levels (cmax) of ubiquinol. The relative bioavailability calculated using the area under the curve (AUC0-24h) was also increased by 485%.

Cardiology studies with CoQ10 include research on congestive heart failure, ischemic heart disease, and hypertensive heart disease. Supplemental CoQ10 has been found to alter the natural history of cardiovascular illnesses and has the potential for prevention of cardiovascular disease. One recent study reviewed 34 controlled trials and several other studies on CoQ10’s positive effects on cardiovascular disease. Other studies have focused on its antioxidant properties and on its role in recovery from heart attack, improved heart function post-attack, and their positive effect on patients with congestive heart failure, and on its role in decreasing LDL cholesterol oxidation.

References:

Z. Xian-Liu et al. Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System (CoQsource®). Alternative Therapies in Health & Medicine 15(2) 2009, 42-46.
Bhagavan HN, Chopra RK. Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetic. Free Radical Research 2006; 40(5):445-453.
Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 2007; 7S:S78-S88.
Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative Bioavailability of Coenzyme Q10 formulations in Human Subjects. Int J Vit Nutr Res 1998; 68: 109-113.
Miles MV, Horn P, Miles L, Tang P, Steele P, DeGrauw T. Bioequivalence of coenzyme Q10 from over-the-counter supplements. Nutr Res 2002; 22:919-929.
Molyneux S, Florkowski C, Lever M, George P. The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly. N Z Med J 2004; 117(1203):U1108
Ullmann U, Metzner J, Schulz C, Perkins J, Leuenberger B. A New Coenzyme Q10 Tablet- Grade Formulation (all-Q®) Is Bioequivalent to Q-Gel® and Both Have Better Bioavailability Properties than Q-SorB®. J Med Food 2005; 8(3):397-399.
Schulz C, Obermüller-Jevic UC, Hasselwander O, Bernhardt J, Biesalski HK. Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (SoluTM Q10). Int J Food Sci Nutr 2006; 57(7/8): 546-555.
Nukui K, Yamagishi T, Miyawaki H, Kettawan A, Okamoto T, Sato K. Comparison of Uptake between PureSorb-QTM40 and Regular Hydrophobic Coenzyme Q10 in Rats and Humans after Single Oral Intake. J Nutr Sci Vitaminol 2007; 53:187-190.
Wajda R, Zirkel J, Schaffer T. Increase of Bioavailability of Coenzyme Q10 and Vitamin E. J Med Food 2007; 10(4):731-734
Zmitek J, Smidovnik A, Fir M, Prosek M, Zmitek K, Walczak J, Pravst I. Relative Bioavailability of Two Forms of a Novel Water-Soluble Coenzyme Q10. Ann Nutr Metab 2008; 52:281-287.
Zita C, Overvad K, Mortensen SA, Sindberg CD, Moesgaard S, Hunter DA. Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomized controlled study. BioFactors 2003; 18:185-193.
Singh RB, Niaz MA, Kumar A, Sindberg CD, Moesgaard S, Littarru. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. BioFactors 2005; 25:21-9-224.
Shults CW, Beal MF, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Experimental Neurology 2004; 188:491- 494.
Kaikkonen J, Nyyssönen K, Porkkala-Sarataho E, Poulsen HE, Metsä-Ketelä T, Hayn M, Salonen R, Salonen JT. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL + LDL fraction: Absorption and antioxidative properties of oil and granule-based preparations. Free Radical Biology & Medicine 1997; 22(7):1195-1202.
Shults, C.W., Oakes, D., Kieburtz, K., Beal, M.F., Haas, R., Plumb, S., Juncos, J.L., Nutt, J., Shoulson, I., Carter, J., Kompoliti, K., Perlmutter, J.S., Reich, S., Stern, M., Watts, R.L., Kurlan, R., Molho, E., Harrison, M., Lew, M. Effect of Coenzyme Q10 in early Parkinson disease. Arch. Neurol. 2002; 59: 1541-1550.
Langsjoen PH, Langsjoen AM. Supplemental Ubiquinol in patients with advanced congestive heart failure. Accepted for publication and in print in BioFactors 2008.
Williams, K.D., Maneke, J.D., AbdelHameed, M., Hall, R.L., Palmer, T.E., Kitano, M., Hidaka, T. 52-week oral gavage chronic toxicity study with ubiquinone in rats with a 4-week recovery. J. Agric. Food Chem. 1999; 47: 3756-3763.
The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001; 57: 397-404.
Baggio, E., Gandini, R., Plancher, A.C., Passeri, M., Carmosino, G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Mol. Aspects Med. 1994; 15: s287-s294.
Ikematsua H., Nakamura K., Harashima S., Fujii K, Fukutomi N. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: A double-blind, randomized, placebo- controlled trial. Regulatory Toxicology and Pharmacology 2006; 44:212-218.